Perspectives on reticular pseudodrusen in age-related macular degeneration
S Sivaprasad, A Bird, R Nitiahpapand… - Survey of …, 2016 - Elsevier
Drusen have been considered the clinical hallmark of age-related macular degeneration
(AMD). Reticular pseudodrusen (RPD), although first described about 25 years ago, have …
(AMD). Reticular pseudodrusen (RPD), although first described about 25 years ago, have …
Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications …
JI Patel, J Tombran-Tink, PG Hykin, ZJ Gregor… - Experimental eye …, 2006 - Elsevier
The aim of the study was to determine anatomical and growth factor profiles in patients with
clinically significant macular oedema (CSMO) undergoing pars plana vitrectomy (PPV) …
clinically significant macular oedema (CSMO) undergoing pars plana vitrectomy (PPV) …
Diabetic cataract removal: postoperative progression of maculopathy—growth factor and clinical analysis
JI Patel, PG Hykin, IA Cree - British Journal of Ophthalmology, 2006 - bjo.bmj.com
Background: Diabetic cataract extraction can be frequently complicated by macular oedema,
progression of retinopathy, or development of iris neovascularisation. The pathogenesis of …
progression of retinopathy, or development of iris neovascularisation. The pathogenesis of …
Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser …
M Michaelides, S Fraser-Bell, R Hamilton, A Kaines… - Retina, 2010 - journals.lww.com
Purpose: The purpose of this study was to assess macular perfusion with fundus fluorescein
angiography at the 4-month time point in a prospective randomized, single-center 2-year …
angiography at the 4-month time point in a prospective randomized, single-center 2-year …
[HTML][HTML] Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration
R Gohil, R Crosby-Nwaobi, A Forbes, B Burton… - PloS one, 2015 - journals.plos.org
Purpose To assess the caregiver burden and factors determining the burden in patients
receiving ranibizumab therapy for neovascular AMD (nAMD). Methods This is a cross …
receiving ranibizumab therapy for neovascular AMD (nAMD). Methods This is a cross …
Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)
S Sivaprasad, R Crosby-Nwaobi, LZ Heng… - British Journal of …, 2013 - bjo.bmj.com
Aims To explore the parameters that influence injection frequency in patients treated with
intravitreal bevacizumab (ivB) for diabetic macular oedema. Injection frequency was …
intravitreal bevacizumab (ivB) for diabetic macular oedema. Injection frequency was …
Novel mutations and electrophysiologic findings in RGS9-and R9AP-associated retinal dysfunction (Bradyopsia)
M Michaelides, Z Li, NA Rana, EC Richardson… - Ophthalmology, 2010 - Elsevier
PURPOSE: To examine the phenotypes of 8 patients with evidence of cone dysfunction and
normal color vision (characteristic features of both oligocone trichromacy and bradyopsia) …
normal color vision (characteristic features of both oligocone trichromacy and bradyopsia) …
Evolution of fundus autofluorescence patterns over time in patients with chronic central serous chorioretinopathy
M Zola, I Chatziralli, D Menon, R Schwartz… - Acta …, 2018 - Wiley Online Library
Purpose To determine the evolution of fundus autofluorescence (FAF) patterns in chronic
central serous chorioretinopathy (CSCR) over time. Methods We retrospectively studied the …
central serous chorioretinopathy (CSCR) over time. Methods We retrospectively studied the …
De novo mutations in the 5′ regulatory region of the Norrie disease gene in retinopathy of prematurity
SJ Talks, N Ebenezer, P Hykin, G Adams… - Journal of Medical …, 2001 - jmg.bmj.com
EDITOR—Retinopathy of prematurity (ROP) is the commonest cause of potentially
preventable blindness in infants. 1 2 In developed countries this may reflect the increasing …
preventable blindness in infants. 1 2 In developed countries this may reflect the increasing …
Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept
I Chatziralli, L Nicholson, E Vrizidou, C Koutsiouki… - Ophthalmology, 2016 - Elsevier
Purpose The purpose of this study was to evaluate the outcomes over 12 months in patients
with neovascular age-related macular degeneration (nAMD) with insufficient response to …
with neovascular age-related macular degeneration (nAMD) with insufficient response to …